Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioHarvest Sciences Inc. is a biotechnology company focused on plant-based nutraceuticals and functional health products. The company operates at the intersection of agricultural biotechnology, nutritional supplements, and consumer health, using proprietary technology to grow plant cells in controlled environments rather than traditional farming. Its core commercial focus is the development and sale of science-backed nutraceutical ingredients and finished consumer products derived from botanical compounds.
The company’s primary revenue driver is its nutraceutical product portfolio, most notably products based on red grape cells rich in polyphenols. BioHarvest’s technology platform, branded as Bio-Plant Cell Expansion™ Technology, enables the production of active plant compounds without pesticides, seasonal constraints, or agricultural land dependency. Founded in 2007, the company initially focused on agricultural yield enhancement before pivoting toward nutraceutical and wellness applications, culminating in commercial product launches and public listing on U.S. markets.
Business Operations
BioHarvest operates through two principal business activities: commercial nutraceutical sales and ongoing biotechnology research and development. Revenue is primarily generated through the sale of finished nutraceutical products under the VINIA® brand, which is marketed for cardiovascular and metabolic health benefits, as well as bulk ingredient supply to partners. The company maintains vertically integrated control over cultivation, processing, and formulation using its proprietary plant-cell growth systems.
Operations are conducted through wholly owned subsidiaries, including BioHarvest Ltd., which houses the company’s core research, development, and manufacturing activities. Production relies on controlled bioreactor-based cultivation rather than open-field agriculture, allowing consistent output and traceability. As of available public disclosures, the company has limited but growing international commercial distribution, with a significant portion of sales directed toward direct-to-consumer channels.
Strategic Position & Investments
Strategically, BioHarvest positions itself as a differentiated player in the nutraceutical market by emphasizing scientifically validated ingredients, sustainability, and supply-chain independence from traditional agriculture. Growth initiatives have centered on expanding consumer adoption of VINIA®, increasing production capacity, and pursuing clinical research to substantiate health claims, particularly in cardiovascular health.
The company has invested heavily in scaling its proprietary Bio-Plant Cell Expansion™ Technology platform, with ongoing efforts to apply the technology to additional plant species beyond red grapes. No material acquisitions have been publicly confirmed in recent filings; however, internal investment has focused on intellectual property development, manufacturing automation, and regulatory compliance. Data inconclusive based on available public sources regarding any undisclosed joint ventures or minority investments.
Geographic Footprint
BioHarvest Sciences Inc. is headquartered in British Columbia, Canada, with its primary research and manufacturing operations located in Israel. This geographic structure supports both North American capital markets access and proximity to Israel’s biotechnology research ecosystem. Commercial activities are concentrated in North America, particularly the United States, which represents the company’s largest customer market.
The company maintains a limited but expanding international footprint, with distribution capabilities extending into select markets in Europe and other regions through online and partner-driven channels. Manufacturing and R&D remain centralized, with no publicly confirmed large-scale manufacturing facilities outside Israel as of the latest verified disclosures.
Leadership & Governance
BioHarvest is led by a management team with experience spanning biotechnology, pharmaceuticals, and consumer health. The leadership emphasizes a strategy centered on scientific validation, capital efficiency, and long-term scalability of proprietary technology platforms. Governance follows standard public-company oversight practices consistent with U.S. reporting issuers.
Key executives include:
- Ilan Sobel – Chief Executive Officer
- Dr. Shmuel Wasser – Chief Science Officer
- David Ryan – Chief Financial Officer
- Yochanan Shachnai – Chairman of the Board
The leadership team has consistently articulated a vision focused on transforming how plant-based bioactive compounds are produced and commercialized, prioritizing sustainability, consistency, and clinically supported outcomes.